Owkin Announces Availability of K Pro in the AWS Marketplace SaaS Category
13.11.2025 14:00:00 CET | Business Wire | Press Release
Owkin, a leading provider of agentic AI solutions for biopharma, today announced the availability of K Pro in the SaaS category of AWS Marketplace. Customers can now use AWS Marketplace to easily discover, buy, and deploy AI agents solutions, including Owkin’s agentic AI co-pilot for biopharma using their AWS accounts, accelerating agent and agentic workflow development.
K Pro helps organizations make smarter decisions across their discovery and development pipeline by delivering decision-grade, data-driven biological insights, enabling customers to increase clinical success rates and change program trajectories.
"By offering K Pro in AWS Marketplace we're providing customers with a streamlined way to access our agentic AI co-pilot, helping them buy and deploy agent solutions faster and more efficiently." said Adi Ravia, Head of Product at Owkin. "Our customers in biotech, pharmaceuticals and research are already using these capabilities to access and analyse deep multimodal patient data, understand and review the scientific literature and uncover treatment-relevant biomarkers, demonstrating the real-world value of K Pro."
K Pro delivers essential capabilities including natural language interaction, biological reasoning, and proprietary multimodal data access. These features enable customers to unify fragmented workflows into an insight-driven research experience.
With the availability of SaaS in AWS Marketplace, customers can significantly accelerate their procurement process to drive AI innovation, reducing the time needed for vendor evaluations and complex negotiations. With centralized purchasing using AWS accounts, customers maintain visibility and control over licensing, payments, and access through AWS.
To learn more about K Pro in AWS Marketplace, visit https://aws.amazon.com/marketplace/pp/prodview-janhwocmshmxm.
About Owkin: Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Artificial Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is K Pro, an AI copilot and its new LLM finetuned on biology called OwkinZero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251113162741/en/
Contacts
To request an interview with Owkin and AWS, please contact aws.france@wpp.com.
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
South African Agency Boundless Delivers Mazda’s First AI-produced Commercial Using Luma Agents15.4.2026 21:07:00 CEST | Press Release
Luma AI today announced that Boundless, an independent creative agency based in Johannesburg, South Africa, has produced Mazda’s first AI-produced commercial using Luma Agents, Luma’s AI-powered creative workflow system. Delivered in less than two weeks from initial brief to final approval, the project marks a significant step in the use of AI-native workflows for commercial production. As part of the collaboration, Boundless has also signed an agreement with Luma to integrate the company’s AI technologies into its creative workflow across future client work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415098939/en/ The project marks a milestone for both Boundless and the broader advertising industry, demonstrating how AI-native workflows can help agencies compress production timelines while maintaining creative quality, brand consistency, and operational oversight. The campaign supports the re-entry of the Mazda MX-5
Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release
The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta
Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy15.4.2026 17:29:00 CEST | Press Release
The Board of Directors ofPIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens. The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for susta
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample15.4.2026 16:00:00 CEST | Press Release
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President: Makoto Manabe)); Takashi Kikuchi (Application Laboratories, Global Product Unit, Rigaku Corporation, a group company of Rigaku Holdings); Futa Sakakibara (Technical Advisor, R&D Support Division, Asterism G.K.); Yoshinori Murai (Senior curator, Department of Botany, National Museum of Nature and Science); and colleagues have successfully determined the structures of more than ten phenolic glycosides from a tiny sample of an alpine plant flower by developing a trace analysis method. This achievement is particularly significant because alpine plants are typically small and difficult to collect due to legal, ethical, and environmental considerations, resulting in extremely limited sample availability. Determining the structures of numerous chemical components from such a small sample repres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom